Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review

BACKGROUND AND OBJECTIVES: Short-term studies focused on once-monthly paliperidone palmitate (PP) at doses of 25 mg eq, 50 mg eq, 75 mg eq, 100 mg eq, or 150 mg eq have shown its efficacy and tolerability in the treatment of schizophrenia patients. However, few open-label and long-term studies are a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Patient Prefer Adherence
Main Authors: González-Rodríguez, Alexandre, Catalán, Rosa, Penadés, Rafael, Garcia-Rizo, Clemente, Bioque, Miquel, Parellada, Eduard, Bernardo, Miquel
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2015
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459629/
https://ncbi.nlm.nih.gov/pubmed/26082620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S63948
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados